A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Submitted: May 21, 2020
Accepted: June 23, 2020
Published: August 6, 2020
Abstract Views: 918
PDF: 669
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the effectiveness of omalizumab in a multicentre group of patients with Samter’s triad. We retrospectively enrolled eight patients (5 females) with Samter’s triad who underwent at least one year of omalizumab therapy. Clinical data, functional parameters and questionnaires for asthma and nasal polyposis control were collected at baseline and follow-up.  We observed a significant reduction of moderate-to-severe asthma exacerbations, together with an increase of FEV1 and a reduction of steroids intake. An improvement in asthma control and nasal symptoms was also reported. This multicenter study confirms the effectiveness of omalizumab in patients affected by Samter’s triad. Omalizumab may represent a potential therapeutic option for the management of this disease. 

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Cameli, Paolo, Miriana d’Alessandro, Laura Bergantini, Elena Silvestri, Arianna Romaldi, Giacomo Emmi, Paola Parronchi, and Elena Bargagli. 2020. “A Multicenter Approach to Evaluate Omalizumab Effectiveness in Samter’s Triad”. Monaldi Archives for Chest Disease 90 (3). https://doi.org/10.4081/monaldi.2020.1397.